miR-21 |
VEGF |
Enhance the VEGF and angiogenesis |
[19] |
Exosome-derived lung cancer |
NF-ĸB-TLR signaling |
Mesenchymal stem cells can be transformed into a pro-inflammatory phenotype |
[20] |
EGFR |
|
Stimulate tumor-specific regulatory T cells that can limit the role of anti-tumor CD-positive T cells |
[21] |
Exosome-derived lung cancer |
|
Induce EMT in human bronchial epithelial cells |
[22] |
Integrin α6β4 and α6β1 |
|
Organ-specific lung metastasis |
[24] |
miR-222-3p |
|
Promote gemcitabine resistance |
[25] |
EGFR |
|
Inhibit function of CD-positive T cell |
[21,26] |
PD-L1 |
PD-1 |
Avoid immune surveillance and CD8+ T cells |
[27,28] |
Exosome-derived lung cancer |
CCR6, CCR7 and CXCR3 |
Inhibit migration of DCs |
[29] |
Exosome-derived lung cancer |
STAT3, IL-4Rα-STAT6 pathway |
Expand MDSCs and suppress T cell function |
[30] |
Hsp72 |
TLR2/My88 signaling pathway |
Activate MDSCs |
[31] |
miR-21 |
Akt |
Gefitinib resistance |
[32] |